Flexion Therapeutics Inc (NASDAQ:FLXN) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 16, 2016
Zacks Investment Research has downgraded Flexion Therapeutics Inc (NASDAQ:FLXN) to Sell in a statement released on 10/11/2016.
Having a price of $20.45, Flexion Therapeutics Inc (NASDAQ:FLXN) traded 0.48% higher on the day. With the last stock price up 24.67% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. FLXN has recorded a 50-day average of $17.91 and a two hundred day average of $14.97. Trade Volume was up over the average, with 304,698 shares of FLXN changing hands over the typical 250,925
Recent Performance Chart
Flexion Therapeutics Inc has with a one year low of $7.56 and a one year high of $21.71 and has a market capitalization of $0.
A total of 7 brokerages have issued a ratings update on Flexion Therapeutics Inc. Two brokerages rating the company a strong buy, five equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $35.71.
More About Flexion Therapeutics Inc (NASDAQ:FLXN)
Flexion Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company's portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain. The Company's lead product candidate, Zilretta (also known as FX006), is a late-stage, injectable, sustained-release, intra-articular (IA) steroid for patients with moderate to severe OA pain. The Company's other product candidates include FX007, a preclinical, small-molecule tropomyosin receptor kinase A (TrkA) receptor antagonist designed to address post-operative pain, and FX005, a sustained-release p38 mitogen-activated protein (MAP), kinase inhibitor for the treatment of end-stage OA patients. The Company has not generated any revenue.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.